Koss Olinger Consulting LLC Lowers Stock Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)

Koss Olinger Consulting LLC reduced its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,303 shares of the medical instruments supplier’s stock after selling 4,674 shares during the period. Koss Olinger Consulting LLC owned about 0.11% of OraSure Technologies worth $286,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in OraSure Technologies by 27.2% in the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock valued at $3,655,000 after purchasing an additional 183,191 shares during the period. Principal Financial Group Inc. boosted its holdings in OraSure Technologies by 10.7% in the fourth quarter. Principal Financial Group Inc. now owns 73,137 shares of the medical instruments supplier’s stock valued at $264,000 after purchasing an additional 7,077 shares during the period. Franklin Resources Inc. boosted its holdings in OraSure Technologies by 28.5% in the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock valued at $1,091,000 after purchasing an additional 59,723 shares during the period. JPMorgan Chase & Co. boosted its holdings in OraSure Technologies by 5.8% in the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock valued at $3,621,000 after purchasing an additional 46,216 shares during the period. Finally, Barclays PLC boosted its holdings in OraSure Technologies by 182.6% in the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock valued at $836,000 after purchasing an additional 126,503 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR opened at $3.51 on Thursday. The company has a market capitalization of $262.55 million, a price-to-earnings ratio of 23.40 and a beta of -0.02. The business has a 50-day moving average of $3.72 and a two-hundred day moving average of $3.92. OraSure Technologies, Inc. has a 1 year low of $2.69 and a 1 year high of $6.69.

Insiders Place Their Bets

In other news, CFO Kenneth J. Mcgrath bought 64,000 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the completion of the transaction, the chief financial officer now owns 371,013 shares of the company’s stock, valued at approximately $1,168,690.95. This trade represents a 20.85 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John P. Kenny bought 47,659 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the transaction, the director now directly owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. This represents a 204.93 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 190,284 shares of company stock valued at $600,348 in the last ninety days. Insiders own 3.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.